Evolution of the Average Target: Compugen Ltd.

Evolution of the Target Price: Compugen Ltd.

Changes in Analyst Recommendations: Compugen Ltd.

05e1fba57012ab1599.kchx702YOE-8SC8gOfbbmuAbsMgzhHbobAQZxpk6lw8.8PwyqDzaYS6RJ0Rib4SW3b9i0bJWxRqeOD1voutxoF_3hyKcF95aHo0JXA~d72dffc61320e131af095b795fd5fb5e
01-07 HC Wainwright Initiates Compugen at Buy With $4 Price Target MT
13/10/25 Compugen Ltd. to Present Pooled Analysis of COM701 in Three Phase 1 Trials in Patients with Platinum Resistant Ovarian Cancer at ESMO 2025 CI
20/05/24 Truist Securities Trims Price Target on Compugen to $4 From $5, Maintains Buy Rating MT
08/03/24 Truist Securities Adjusts Price Target on Compugen to $5 From $4, Maintains Buy Rating MT
16/05/23 Oppenheimer Adjusts Compugen's Price Target to $7 From $8, Maintains Outperform Rating MT
08/02/23 Jefferies Downgrades Compugen to Underperform From Hold, Lowers Price Target to $0.50 from $2 MT
05/01/23 EF Hutton Initiates Compugen at Buy With $13 Price Target MT
15/11/22 Oppenheimer Adjusts Compugen PT to $8 From $12, Updates Model to Reflect Evolving Development Strategy; Maintains Outperform Rating MT
23/08/22 Truist Securities Adjusts Compugen's Price Target to $4 From $14, Reiterates Buy Rating MT
08/08/22 JMP Securities Adjusts Price Target on Compugen to $4 From $8, Maintains Market Outperform Rating MT
05/08/22 Oppenheimer Adjusts Compugen Price Target to $12 From $14, Maintains Outperform Rating MT
05/08/22 Stifel Adjusts Compugen's Price Target to $5 From $12, Reiterates Buy Rating MT
05/08/22 Jefferies Downgrades Compugen to Hold From Buy; Price Target is $2 MT
25/02/22 SVB Leerink Adjusts Compugen's Price Target to $9 from $16, Maintains Outperform Rating MT
25/02/22 Oppenheimer Adjusts Compugen's Price Target to $14 From $17, Maintains Outperform Rating MT
15/11/21 Oppenheimer Adjusts Compugen PT to $17 From $19, Maintains Outperform Rating MT
06/04/21 Compugen : SVB Leerink Adjusts Price Target on Compugen to $16 From $19, Maintains Outperform Rating MT

Consensus Analysts' recommendations evolution (4 months) Financial estimates divergence Analysts' Target price divergence Objective/dr gap
- - - -
+11.79%
+28.45%
+19.72%
+24.61%
+8.81%
+19.87%
+46.63%
+5.13%
+19.99%
Average +20.56%
Weighted average by Cap. +19.91%


Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
5
Last Close Price
2.310USD
Average target price
4.600USD
Spread / Average Target
+99.13%
High Price Target
6.000USD
Spread / Highest target
+159.74%
Low Price Target
4.000USD
Spread / Lowest Target
+73.16%

Analyst Consensus Detail

Consensus revision (last 18 months)

Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-